News • New imaging agent
HER2-positive breast cancer: Whole-body PET/CT predicts targeted therapy response
A new imaging agent can predict early metabolic response to HER2-targeted treatment in metastatic breast cancer patients, according to new research published in the Journal of Nuclear Medicine.